SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
A phase 3 trial of SKB264 in triple-negative breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
Overview
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT05347134 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 254 participants enrolled, started 2022-06-10 and due to reach its primary completion in 2023-11-30. Interventions recorded: SKB264.
Similar pages
not linked directly; found by shared links- TrialSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB103 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB565 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB118 Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialStudy to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Shares Sichuan Kelun-Biotech and the tag pipeline.